Skip to content
Business Segments · Identifiable assets

Biotechnology — Identifiable assets

Danaher Biotechnology — Identifiable assets decreased by 1.7% to $36.7B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.6%, from $36.12B to $36.7B.

Analysis

StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2020
Last reportedQ1 2026Apr 21, 2026
Rolls up toTotal Assets

How to read this metric

High asset levels relative to revenue may suggest lower asset turnover efficiency.

Detailed definition

The total value of assets that can be directly attributed to the biotechnology segment, including inventory, property, p...

Peer comparison

Standard segment reporting requirement for public companies.

Metric ID: dhr_segment_biotechnology_identifiable_assets

Historical Data

9 periods
 Q4 '21Q4 '22Q4 '23Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$38.12B$37.54B$37.42B$34.61B$36.12B$37.56B$37.3B$37.34B$36.7B
QoQ Change-1.5%-0.3%-7.5%+4.4%+4.0%-0.7%+0.1%-1.7%
YoY Change-1.5%-0.3%-7.5%+7.9%+1.6%
Range$34.61B$38.12B
CAGR-1.9%
Avg YoY Growth+0.0%
Median YoY Growth-0.3%

Frequently Asked Questions

What is Danaher's biotechnology — identifiable assets?
Danaher (DHR) reported biotechnology — identifiable assets of $36.7B in Q1 2026.
How has Danaher's biotechnology — identifiable assets changed year-over-year?
Danaher's biotechnology — identifiable assets increased by 1.6% year-over-year, from $36.12B to $36.7B.
What does biotechnology — identifiable assets mean?
The total value of assets specifically used by the biotechnology segment.